Analysts See $0.20 EPS for Cipher Pharmaceuticals Inc. (CPH) as of May, 10

April 17, 2018 - By Mary Markley

On May, 10 Cipher Pharmaceuticals Inc. (TSE:CPH)’s earnings report is awaited by WallStreet, Faxor reports. This year’s EPS analyst estimate is awaited to be $0.20. That is 122.22 % up compareed to $0.09 EPS for last year. T_CPH’s profit could be $5.34 million with 5.90 P/E in case $0.20 EPS is revealed. 5.26 % EPS growth is what Wall Street’s forecasts after $0.19 reported EPS last quarter. CPH reached $4.72 on during the last trading session after $0.5 change.Cipher Pharmaceuticals Inc. is after having 0.00% since April 17, 2017. CPH has 50,795 volume or 7.26% up from normal. CPH underperformed the S&P500 by 11.55%.

Cipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology firm in South America, Canada, and the United States.The firm is valued at $126.12 million. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.The P/E ratio is 28.96. The firm also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Sitavig, a tablet for the treatment of herpes labialis in immunocompetent adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: